A B S T RA CT The antibiotic ristocetin, in concentrations of 1.0-1.5 mg/ml, aggregated normal platelets in citrated platelet-rich plasma by a mechanism in which the release reaction played only a minor role. Platelet aggregation by ristocetin in a concentration of 1.2 mg/ ml was absent or markedly decreased in 10 patients with von Willebrand's disease. Lesser degrees of abnormality were obtained with a concentration of 1.5 mg/ml. The magnitude of the defect in ristocetin-induced platelet aggregation correlated well with the degree of abnormality of the bleeding time and the levels of antihemophilic factor (AHF, VIIIAHF) procoagulant activity. In all patients, the defect in ristocetin-induced platelet aggregation was corrected in vitro by normal plasma. Correction was also obtained with a fraction of normal cryoprecipitate that eluted in the void volume with VIIIATF after chromatography on a gel that excludes molecules larger than 5 X 10g. A similar fraction, devoid of VIIIAHF activity, obtained from patients with von Willebrand's disease had no corrective effect, but fractions obtained from patients with hemophilia were just as effective as those obtained from normal subjects. The correction activity of plasma and partially purified factor VIII was inhibited by a rabbit antibody to human factor VIII but not by a human antibody against VIIIAHF procoagulant activity. The studies provide further evidence that patients with von Willebrand's disease are deficient in a plasma factor that is necessary for normal platelet function. The activity of this factor appears to be associated with factor VIII but is unrelated to VIIIAHF procoagulant activity.
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INTRODUCTION
Patients with von Willebrand's disease have a dual defect in their hemostatic mechanism. They are deficient in factor VIII procoagulant activity (antihemophilic factor, AHF,' VIIIAHF)2 and also have a prolonged bleeding time (1) . The cause of the latter is unknown, but the poor retention of platelets in glass bead filters in patients with this disorder (1, 2) suggests a possible de- fect in the ability of platelets to function adequately during the primary arrest of bleeding. Previous studies indicate that the impaired platelet function in this disorder may not be related to an inherent platelet defect but rather to the deficiency of a plasma factor that is required for normal platelet function. Thus, the abnormal platelet retention can be corrected in vitro by normal plasma (3) or cryoprecipitate (4) , and transfusions of these substances may also shorten the bleeding time (4) (5) (6) . Recent studies suggest that these corrective effects are associated with the factor VIII molecule.
For example, studies by Bouma et al. showed the factor in normal plasma that corrects the platelet retention defect elutes in the void volume with VIIIAUF after chromatography on agarose gels that exclude molecules larger than 2 X 106 (7), and we have confirmed these findings (8) . This corrective material, devoid of VIIIAHF, was also present in fractions that eluted in the void volume after chromatography of hemophilic cryoprecipitate (7, 8) but was not found after chromatography of cryoprecipitate from patients with von Willebrand's disease (8) .
Howard and Firkin have recently presented further evidence that platelet function is defective in von Willebrand's disease. They found that the addition of the antibiotic ristocetin to normal platelet-rich plasma results in platelet aggregation but that aggregation was decreased in two out of three patients with von Willebrand's disease (9) . We present herein studies on the mechanism that may be involved in the aggregation of platelets by ristocetin, the results of ristocetin-induced platelet aggregation obtained in 10 patients with von Willebrand's disease, and findings that demonstrate that the abnormality of platelet aggregation in this disorder can be specifically corrected by a factor present in both normal and hemophilic plasma, which appears to be associated with factor VIII.
METHODS
Subjects. 10 patients with the typical findings of von Willebrand's disease (1) were studied (Table I) . These consisted of a prolonged bleeding time, decreased VIIIAHF activity and decreased retention of platelets in glass bead filters, as determined by previously described methods (1, 4) . In the present study, VIIIAHIF levels were expressed as units per 100 ml rather than as percent activity. 1 U of VIIIAHF is the amount present in 1 ml of the pooled, normal plasma used as the reference standard. Control subjects were fifteen normal subj ects of both sexes, ages 1945. Other patients with bleeding disorders who were studied had Glanzmann's thrombasthenia (10), classical hemophilia, and storage-pool disease (11, 12) . In the latter disorder, collagen-induced platelet aggregation is defective owning to a deficiency of the metabolically inactive storage pool of adenosine diphosphate which, following its release, is responsible for platelet aggregation. Except where the effect of aspirin was being specifically studied, all subjects were requested to abstain from ingestion of drugs for at least a week prior to testing their blood.
Buffers. Unless otherwise stated, the buffer used in the study was prepared by mixing 1 part of 0.25 M Tris,3 pH 7.3 + 2 parts of 0.85% saline (tris-saline buffer). Platelet aggregation studies. Venous blood was mixed with 1/10 volume of 3.2% sodium citrate in silicone-treated tubes and centrifuged at 1,500 g and 200C for 3 min to obtain platelet-rich plasma (PRP). Platelet-poor plasma (PPP), obtained by centrifuging PRP for 30 min in an International PR-J centrifuge at 2,400 g and 4'C, was used as the blank in the platelet aggregation studies and to assess the corrective effects of plasma. Platelet aggregation was studied by stirring 1.9 ml of PRP + 0.08-0.10 ml of the aggregating agent in a dual channel aggregometer equipped with a no. 609 deep red filter (Payton Associates, Buffalo, N. Y.), and results were recorded on a RikenDenshi recorder (Tokyo, Japan). Platelet aggregation was expressed as the percent change in optical density 6 min after addition of the aggregating agent (13 Inhibitors of platelet aggregation,. The following substances were tested: adenosine (obtained from Sigma Chemical Co.), Na2 EDTA, KCN, 2-deoxy-D-glucose (Aldrich Chemical Co., Inc., Milwaukee, Wisc.) and sodium heparin (Upjohn Co., Kalamazoo, Mich.).
Treatment of plasma. PPP was incubated for 10 min at room temperature with 1/10 volume of Al(OH)3 (Cutter Laboratories, Berkeley, Calif.) or with Celite 512, 30 mg/ ml (Johns Manville, New York). PPP was also incubated at 370 for varying periods of time. Cryoprecipitate was prepared as described previously (4) and was resuspended in the initial plasma volume with Tris-saline buffer. Serum was prepared from PPP by incubating for 1 h at 370C the following mixture: 1.8 ml PPP + 0.1 ml 8% kaolin + 0.1 ml lipid (Platelin, a chloroform extract of brain obtained from Warner-Chilcott Laboratories, Morris Plains, N. J.) + 0.1 ml 0.025 M CaCl2. Agarose gel chromatography. A glass column (2.5 X 60 mm) was packed with Bio-Gel 5M, 200 mesh (Bio-Rad Laboratories, Richmond, Calif.) to a gel height of 50 cm and equilibrated with a buffer containing one part of 0.253 M imidazole and nine parts of 0.85%o saline. The buffer, adjusted with 1M HCI, gave a pH of 6.9 at 220C and 7.3 at 4°C. Cryoprecipitate obtained from 40 ml of plasma was dissolved in 2.0 ml of supernatant plasma. This was applied to the top of the column, and the column was eluted with buffer by gravity flow, by means of a Mariotte flask, at a pressure head of 56 cm. All procedures were performed at 4VC. The flow rate was 0.16-0.19 ml/min, and column fractions of 2.3-2.7 ml were assayed for VIIIAHF-activity and protein (ODm0) as previously described (17) . The corrective effects of the fractions on ristocetin-induced platelet aggregation were tested on the day of collection. The agarose gel used excludes molecules whose molecular weight is greater than 5 X 108, and the void volume of the column was determined with Salmonella typhosa lipopolysaccharide, mol wt 1.5 X 108 (Difco Laboratories, Detroit, Mich.).
Antibodies to factor VIII. A monospecific rabbit antibody to purified human factor VIII (rabbit anti-VIII), the properties of which have been described (18) , was obtained from Dr. Leon Hoyer of the University of Connecticut School of Medicine. We also used plasma from a hemophiliac with an antibody to factor VIII (human anti-VIII). Incubation of 0.9 ml of normal human plasma with 0.1 ml of the rabbit anti-VIII for 30 min at 370C reduced the VIIIAHF activity from 110 to 7%, while a similar incubation with the human anti-VIII reduced the VIIIAHF activity from 110 to 2.5%. The inhibitory effects of both human and rabbit antibodies were specific for factor VIII; incubation with plasma had no effect on any other clotting factors.
RESULTS
Ristocetin-induced aggregation of normal platelets.
The addition of ristocetin to normal PRP resulted in im- mediate platelet aggregation (Fig. 1) . The lowest final concentration of ristocetin that produced some visible increase in light transmission on the aggregometer tracing varied but was generally between 0.8 and 1.0 mg/ml. With a concentration of 1.0-1.2 mg/ml, an initial slow rate of aggregation during the first 2-3 min was fol- disease was corrected by hemophilic plasma (Fig. 3C and (Table IV) . In addition, the corrective effect of normal plasma and of the HMW fraction derived therefrom (factor VIII) was not destroyed by a human anti-VIII that was a potent inhibitor to VIIIAHF procoagulant activity (Table IV) .
Ristocetin-induced platelet aggregation in other platelet disorders. Platelet aggregation curves, obtained with a ristocetin concentration of 1.2 mg/ml, are depicted in Fig. 5 . Among congenital disorders, ristocetin-induced aggregation was decreased to a variable degree in two patients with Glanzmann's thrombasthenia. A subtle type of defect was present in patients with storage-pool disease and in normal subjects after aspirin ingestion. The initial slow phase of ristocetin-induced aggregation was normal. However, the slope of the more rapid phase was consistently decreased. Despite this lower rate of aggregation, the total amount of platelet aggregation at 6 min was the same as in normal subjects. Unlike the findings in von Willebrand's disease, none of the above abnormalities were corrected by the addition of normal plasma.
Ristocetin-induced aggregation was normal in hemophilia.
Effects of other platelet-aggregating substances in von Willebrand's disease. Platelet aggregation by polylysine (0.0S-0.10 mg/ml) was the same in patients with von Willebrand's disease as in normal subjects. The addition of concanavalin A in a final concentration of 3 mg/ml to both normal and von Willebrand PRP resulted in platelet aggregation after a lag period of 2-3 min.
DISCUSSION
Ristocetin is an antibiotic that is obtained from the actinomycete Nocardia lurida and is active against gram positive bacteria and mycobacteria (20, 21) . Because of the high incidence of thrombocytopenia that was associated with its use (22) it is now rarely employed in clinical medicine. Gangarosa, Jolnson, and Ramos were the first to report that ristocetin caused microscopic platelet agglutination and lysis in vitro (22) . Howard and Firkin extended these observations and further demonstrated that at concentrations in excess of 2 mg/ml ristocetin also precipitates fibrinogen (9) . The results of the present study are in general agreement with those of Howard and Firkin and indicate that human platelets in citrated platelet-rich plasma are aggregated by ristocetin in concentrations, ranging from 1.0-1.5 mg/ml, that do not precipitate fibrinogen.
The observation that ristocetin did not release LDH, a cytoplasmic enzyme (23) , indicates that under the conditions of this study, the antibiotic does not produce platelet lysis. The type of platelet aggregation produced by ristocetin has some features that are similar to those associated with ADP-induced aggregation. For example, ristocetin-induced aggregation is immediate and is inhibited by adenosine and by combined inhibition of both respiration and glycolysis (24) . However, aggregation was only partially inhibited by a concentration of EDTA that completely blocks ADP-induced aggregation; conversely, it was totally blocked by a concentration of KCN that only partially inhibited ADP-induced aggregation, in confirmation of previous observations of Howard and Firkin (9) . In addition, ristocetin produced a small amount of platelet aggregation in patients with Glanzmann's thrombasthenia, in contrast to the total absence of ADP-induced aggregation in this disorder (10) . Unlike collagen-induced platelet aggregation, the release reaction appears to play only a minor role in ristocetininduced aggregation, particularly in its early phase. For example, a significant amount of aggregation, occurring within 2 min of the addition of ristocetin, was associated with only a minimal release of either platelet ADP or serotonin. Substantial amounts of ADP (and relatively lesser amounts of serotonin) were released during a later stage of platelet aggregation; this released ADP may play some role in ristocetin-induced aggregation. Fig. 4 . In normal cryoprecipitate, this fraction coincided with the peak of the VIIIALAF activity.
ther support of this possibility was the finding that the rate of platelet aggregation during the rapid phase of ristocetin-induced aggregation was somewhat decreased in normal subjects in whom the release mechanism had been inhibited by aspirin ingestion (13) and in patients whose platelets are deficient in the storage-pool of ADP (11, 12) . In neither case, however, was this decrease sufficient to reduce the total amount of platelet aggregation that eventually occurred. The mechanism by which ristocetin aggregates platelets is not yet known. Previous studies have shown that ristocetin inhibits the synthesis of peptidoglycans in bacterial cell walls either by steric interference with their polymerization or by forming stable complexes with mucopeptide precursors (25) (26) (27) . Whether similar interactions with the platelet surface are involved in ristocetin-induced platelet aggregation remains to be determined. Ristocetin-induced platelet aggregation was decreased in 10 patients with von Willebrand's disease; this confirms the previous findings of Howard and Firkin, who reported decreased aggregation in two out of three patients with this disorder (9) . In a more recent paper, these authors have reported decreased aggregation in 9 of 14 patients with von Willebrand's disease (28) correlation between the degree of abnormality of the bleeding time and VIIIAHF level on the one hand and the magnitude of the defect in ristocetin-induced aggregation on the other. This correlation suggests that the prolonged bleeding time in von Willebrand's disease is somehow related to a defect in the formation of a hemo-static platelet aggregate during the primary arrest of the bleeding. Baumgartner has developed and described a method for studying the adhesion of platelets in flowing blood to the subendothelium of rabbit aorta (29) , and, using this method, we have recently found a significant defect of platelet adhesion in five patients with von Willebrand's disease (30) . Since the interaction of platelets with collagen appears to be normal in von Willebrand's disease (1), these findings suggest that their nonadhesion to some other vascular component may account for the hemostatic defect in this disorder. How this may be related to an abnormality in ristocetin-induced platelet aggregation is not clear. Possibly, similar functional groups on the ristocetin molecule and vascular components may be involved.
The present study lends further support to the possibility suggested in previous studies that the defect in hemostasis and platelet function in von Willebrand's disease is not owing to an intrinsic platelet defect but rather to a deficiency of a plasma factor necessary for normal platelet function (3, 4, 7, 8) . The abnormality of ristocetin-induced platelet aggregation in all patients was corrected by the addition of normal plasma. This correction factor eluted in the void volume with VIIIAHw procoagulant activity after chromatography on Bio-Gel 5M, and its ability to correct the defect in platelet aggregation in von Willebrand's disease was destroyed by a rabbit antibody to human factor VIII. These findings suggest that the correction factor (von Willebrand factor, VWF) may be associated with the factor VIII molecule (VIIIvwr). The (15) . The quantitative relationships which were found between VIIIAHF, VIIIvwF, and VIIIAGN in normal subjects and in patients with von Willebrand's disease are the subject of an accompanying paper (15) .
Finally, the mechanisms whereby factor VIII, a glycoprotein (33) is necessary for ristocetin-induced aggregation requires clarification. At higher concentrations than those required to aggregate platelets, ristocetin precipitates fibrinogen. We studied the effects on platelets of polylysine, which also precipitates fibrinogen (34) , and concanavalin A, which precipitates factor VIII and other glycoproteins (33) . Platelet aggregation by these two substances was the same in patients with von Willebrand's disease as in normal subjects; the mechanisms involved in platelet aggregation by these agents and by ristocetin are apparently different. Further studies on the nature of the interaction that may occur among ristocetin, factor VIII and platelets may help to clarify the mechanisms involved in ristocetininduced aggregation and to provide useful information about the hemostatic defect in von Willebrand's disease.
